CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04963569
NCT04963569N/ACompleted

Mechanistic Inflammatory Sub-study Embedded Within the Albumin vs Balanced Crystalloid Trial

University of Edinburgh·observational·Posted Jul 15, 2021·Updated Apr 15, 2025

In Brief

An observational study for Sepsis. Completed, enrolled 26 participants across 1 site.

Detailed Summary

MIS-ABC Sepsis is a sub-study looking to understand how the immune response in patients with infection changes during the early stages of the illness, as well as after intravenous fluid treatment. Participants in the main trial will be given one of two types of fluid (Human Albumin Solution (HAS) and Balanced Crystalloid) via a drip when they present to the hospital with severe infection (sepsis). The main trial is assessing which fluid is better, and we are going to take three blood samples around the time people come to hospital to see what happens to their immune system as a result of the infection and fluid treatment. We hope our findings will explain why one fluid might be better than another. It may also give us an important information about whether we can predict which people might get sicker despite treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSepsis
CountriesUnited Kingdom

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJul 15, 2021
Enrollment StartDec 13, 2021
Primary CompletionJun 8, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.0 years ago